BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) Director John Schmid purchased 6,000 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $96,000.00. Following the transaction, the director directly owned 6,000 shares in the company, valued at approximately $96,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
BlossomHill Therapeutics Stock Up 3.3%
NASDAQ:BLSM opened at $16.52 on Wednesday. BlossomHill Therapeutics, Inc. has a 52 week low of $15.25 and a 52 week high of $17.25.
Read More
- Five stocks we like better than BlossomHill Therapeutics
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
